How big is MiMedx Group, Inc.?

As of Jun 18, MiMedx Group, Inc. has a market capitalization of 868.60 million, with net sales of 352.38 million and a net profit of 39.96 million over the latest four quarters. The balance sheet shows shareholder's funds of 193.11 million and total assets of 263.92 million.

As of Jun 18, MiMedx Group, Inc. has a market capitalization of 868.60 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 352.38 million for the latest four quarters, along with a net profit of 39.96 million during the same period.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds amounting to 193.11 million and total assets of 263.92 million.

What does MiMedx Group, Inc. do?

MiMedx Group, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $88 million and a net profit of $7 million. Key metrics include a market cap of $868.60 million, a P/E ratio of 24.00, and a return on equity of 19.84%.

Overview: <BR>MiMedx Group, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 88 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 7 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 868.60 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 24.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.43 <BR>Return on Equity: 19.84% <BR>Price to Book: 4.28<BR><BR>Contact Details: <BR>No Company Details Available. <BR>Registrar Address: Not available.

Should I buy, sell or hold MiMedx Group, Inc.?

Is MiMedx Group, Inc. technically bullish or bearish?

As of October 31, 2025, MiMedx Group, Inc. shows a mildly bullish trend driven by positive weekly MACD and Bollinger Bands, despite mixed signals from daily moving averages and monthly RSI, while it has outperformed the S&P 500 recently but underperformed year-to-date.

As of 31 October 2025, the technical trend for MiMedx Group, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bearish, indicating mixed signals across time frames. The Bollinger Bands are mildly bullish on both weekly and monthly charts, supporting the bullish stance. However, the daily moving averages remain mildly bearish, which tempers the overall bullish outlook. The RSI shows no signal on the weekly and bearish on the monthly, suggesting caution. <BR><BR>In terms of performance, MiMedx has outperformed the S&P 500 over the past week and month, with returns of 14.26% and 6.66% respectively, but it has underperformed on a year-to-date basis with a return of -20.06% compared to the S&P 500's 16.30%. Overall, the current technical stance is mildly bullish, driven by the weekly MACD and Bollinger Bands, despite some bearish indicators on the daily moving averages and monthly RSI.

Is MiMedx Group, Inc. overvalued or undervalued?

As of November 21, 2025, MiMedx Group, Inc. is fairly valued with a P/E ratio of 24, despite a recent downgrade from attractive, showing strong long-term returns of 111.87% over three years but a short-term decline of -29.52% year-to-date.

As of 21 November 2025, the valuation grade for MiMedx Group, Inc. has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be fairly valued at this time, with a P/E ratio of 24, an EV to EBIT of 16.13, and an EV to EBITDA of 14.64. In comparison to peers, LeMaitre Vascular, Inc. has a higher P/E ratio of 49.77, while Alphatec Holdings, Inc. shows a negative P/E, highlighting the variability in the sector.<BR><BR>Despite the recent downgrade in valuation, MiMedx has demonstrated strong returns over the long term, with a 3-year return of 111.87% compared to the S&P 500's 67.17%. However, it has struggled in the short term, with a year-to-date return of -29.52% against the S&P 500's 12.26%. This mixed performance reinforces the notion that while the company is currently fairly valued, its recent stock performance may warrant caution for potential investors.